Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 2, Randomized, Placebo-controlled, Dose-ranging Study of the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AG10 in Patients With Symptomatic Transthyretin Amyloid Cardiomyopathy

Trial Profile

A Phase 2, Randomized, Placebo-controlled, Dose-ranging Study of the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AG10 in Patients With Symptomatic Transthyretin Amyloid Cardiomyopathy

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 10 Nov 2018

At a glance

  • Drugs AG 10 (Primary)
  • Indications Amyloidosis; Cardiomyopathies
  • Focus Adverse reactions
  • Sponsors Eidos Therapeutics
  • Most Recent Events

    • 10 Nov 2018 Results presented in an Eidos Therapeutics media release.
    • 10 Nov 2018 According to an Eidos Therapeutics media release, results from this study were presented at the American Heart Association (AHA) Scientific Sessions.
    • 29 Oct 2018 According to an Eidos Therapeutics media release, the company will host a conference call and webcast on 12th November 2018 to discuss the results of this trial of AG10 in patients with transthyretin amyloidosis cardiomyopathy and symptomatic heart failure. The conference call will will be accessible through an audio webcast at ir.eidostx.com.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top